EGFR and non-small cell lung carcinoma: ,47 Besides, we demonstrated that HLA-LOH was another major influential factor that impair the efficacy of neoadjuvant immunochemotherapy in EGFR-mutant NSCLC, which has also been illustrated in multiple cancer subtypes treated with immunotherapy.48